Synergy Pharmaceuticals

Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013

Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013

Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index

Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index

Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results

Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock

Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock

Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock

Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results

Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013

Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market

Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis

Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals

Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders

Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation

Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases

Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans

Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation

Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans

Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation

Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis

Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis

Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases

Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases

Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation

Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation